The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: A Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group

The combination of estramustine, vinorelbine, and mitoxantrone is safe, well tolerated, and relatively active in patients with hormone-refractory prostate cancer.